ACACB and fatty liver disease: With the advent of phosphorylation-mutant mice, we can now state that phosphorylation of ACC1 and ACC2 is required for inhibition of de novo lipogenesis and activation of FAO to prevent fatty liver, diabetes and hepatocellular carcinoma.